When Pneumonia Leads to Sepsis: Clinical Phenotypes and Therapeutic Challenges

Severe pneumonia is a leading cause of sepsis and mortality in critically ill patients. Pathogen-centred frameworks alone do not explain the marked heterogeneity in clinical presentation and outcomes. Increasing evidence supports a model in which disease progression reflects the interaction between microbial burden, host-response dysregulation, and environmental factors, including viral co-infection and fungal opportunism. This review synthesises current advances in pneumonia-to-sepsis progression, focusing on clinical phenotypes, host-response dynamics, and therapeutic implications.

This narrative review draws on recent literature, prioritising studies from the past decade, particularly the last 2-3 years. Sources included PubMed-indexed publications, clinical trials, observational studies, and consensus guidelines addressing severe community-acquired and nosocomial pneumonia, sepsis, host-response biomarkers, and emerging therapies. Selection was based on relevance to critically ill populations and mechanistic insights into host-pathogen interactions.

Pneumonia is increasingly recognised as a biologically heterogeneous syndrome characterised by distinct host-response phenotypes, ranging from hyperinflammatory to immunosuppressed states, which shape clinical trajectories. Viral infections and fungal opportunism contribute to disease amplification, particularly in the context of epithelial damage and immune dysfunction. While molecular diagnostics improve pathogen detection, they also complicate differentiation between colonisation and infection. Integrative approaches combining microbiology with host-response biomarkers, including markers of endothelial and microcirculatory dysfunction, enhance risk stratification and therapeutic decision-making.

A host-response-integrated framework is essential to advance precision medicine in pneumonia and sepsis. Combining rapid diagnostics with phenotypic stratification may optimise antimicrobial use and enable targeted immunomodulation, improving outcomes while limiting unnecessary exposure.